Biotext Competitors

Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion. Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories. Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients. Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions. The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals. More information is available at www.questdiagnostics.com. Language Assistance / Non-Discrimination Notice Asistencia de Idiomas / Aviso de no Discriminación 語言協助 / 不歧視通知 www.QuestDiagnostics.com/home/nondiscrimination

AIMS: Australia's tropical marine research agency. The Australian Institute of Marine Science (AIMS) is an Australian Government statutory authority established in 1972. AIMS has highly developed capabilities in marine biodiversity, impacts and adaptation to climate change, water quality and ecosystem health. Fisheries, offshore oil and gas, mining, bulk ports, reef tourism and aquaculture industries have all benefited from AIMS research that is geared towards the protection and sustainable development of tropical marine resources. The Institute maintains specialised, world class marine research facilities in Townsville, Perth and Darwin, providing ready access to Australia's tropical coasts and seas. The Institute operates two major vessels, the RV Cape Ferguson and the RV Solander, which support access to ecosystems across the continental shelf, and a fleet of smaller vessels that support near-shore fieldwork . AIMS' research effort is designed to ensure that it is meeting the challenges facing our tropical marine ecosystems and the requirements of our stakeholders.

The origin story of Microbiome Labs is a classic tale of forging new frontiers, complete with discovery, adversity, and a leap of faith. Neither founder set out on a path to start his own supplement company, but through persistent curiosity Dr. Tom Bayne and Microbiologist Kiran Krishnan stumbled upon an amazing opportunity. With Dr. Tom’s clinical expertise and Kiran’s probiotic research, the serendipitous pair formulated the first all-spore probiotic known as MegaSporeBiotic. After a great deal of clinical validation, the team set out to launch the product in the practitioner market by attending medical conferences. In 2014, the company exhibited at only 6 conferences and signed on a handful of new accounts. However, as the product sales began to grow, the company chose to reallocate the majority of the profits back into research, with only a minimal amount leftover for marketing. This unorthodox approach is far and away what continues to set Microbiome Labs apart from the rest of the supplement industry. In doing so, Microbiome Labs hopes to encourage other supplement companies to follow suit, thereby raising the bar of the supplement industry as a whole. In 2018, Microbiome Labs attended over 148 conferences, initiated and/or completed 14 clinical trials, and provided key solutions to thousands of practitioners, changing over 344,000 lives… and counting. Join us in our mission to Make Vibrant Health Accessible for All.